Lord, Abbett & Co
GLMD icon

Lord, Abbett & Co’s Galmed Pharmaceuticals GLMD Stock Holding History

Lord, Abbett & Co’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-794
Closed -$1.39M – 991
2014
Q2 		$1.39M Sell
794
-4
-0.5% -$6.14K ﹤0.01% 973
2014
Q1 		$1.65M Buy
+798
New +$1.87M ﹤0.01% 953

Other funds holding GLMD

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lord, Abbett & Co's GLMD Position: Q3 2014 in Review

Lord, Abbett & Co sold out of Galmed Pharmaceuticals (GLMD) in Q3 2014, closing a stake of 794 shares — an estimated $1.39M sold.

Lord, Abbett & Co first reported a position in GLMD in Q1 2014 and held it in 2 quarters. The position peaked at $1.65M in Q1 2014. 19 funds tracked by Wall St. Rank hold GLMD as of Q3 2014.

  • Lord, Abbett & Co reported no remaining Galmed Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Lord, Abbett & Co sold 794 Galmed Pharmaceuticals shares in Q3 2014, an estimated $1.39M.
  • Lord, Abbett & Co first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Lord, Abbett & Co's Galmed Pharmaceuticals position peaked at $1.65M in Q1 2014.
  • 19 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2014.

Based on Lord, Abbett & Co's 13F filing for Q3 2014, filed 14 Nov 2014.